Overview

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Diseas

Status:
Withdrawn

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the percentage of participants with sustained virologic response 12 weeks after the actual end of study treatment (SVR12)

Phase:

Phase 2

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Simeprevir